Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchScilex Holding Company Regains Nasdaq Compliance and Focuses on Innovative Pain Management Solutions.
Jan 21, 2025
DallasBiotechnologyHealth CareMedicalTherapeutics
Product Description
Scilex Holding Company announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report. The company continues to innovate in the development and commercialization of non-opioid pain management products.
Company Information
Company
Nanoscope Therapeutics
Location
1312 BROWN TRAIL
Dallas, Texas, United States
About
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nanoscope Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
DallasBiotechnologyHealth CareMedicalTherapeutics